Latest filing published 14 Mar 2022 for Biocryst Pharmaceuticals INC, €2.4M.
Filing timeline
BuySaleInsider track record
Closed purchases
Not enough history yet: 0 closed purchases, at least 2 are needed.
Purchases by company
William P. Sheridan: trading record in brief
William P. Sheridan (senior executive) discloses dealings in Biocryst Pharmaceuticals Inc to SEC (Form 4). The record holds 68 filings, for trades running from 30 January 2009 to 10 March 2022.
The open-market side counts 1 purchase for €3,786 alongside 17 sales for €8.3M. The net balance comes to €8.3M on the selling side. Unlike grants, an open-market purchase is paid for by the insider, at the market price. The rest of the record consists of 27 share grants and 23 option exercises. 2022 to date brings no purchases and 2 sales.
The latest filing, published on 14 March 2022, reports an open-market sale of €2.4M in Biocryst Pharmaceuticals Inc. The most recent open-market purchase was published on 3 February 2009, 6,487 days ago. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 3 days. Section 16 rules allow two business days to file each Form 4. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Companies and markets linked to William P. Sheridan
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 159,739 shares@ US$16.8732.9% of flowCommon StockSEC:0001127602-22-009124:1
- 1,400 shares@ US$17.640.3% of flowCommon StockSEC:0001127602-22-009124:2
- 148,302 shares@ US$3.2281.7% of flowCommon StockSEC:0001127602-22-009124:0
- 35,000 shares0Common StockSEC:0001127602-21-031118:0
- 35,701 shares@ US$5.593.3% of flowCommon StockSEC:0001127602-21-018509:1
- 11,099 shares@ US$5.451.0% of flowCommon StockSEC:0001127602-21-018509:2
- 71,759 shares@ US$15.0017.8% of flowCommon StockSEC:0001127602-21-018509:3
- 21,614 shares@ US$4.731.7% of flowCommon StockSEC:0001127602-21-018509:4
- 64,299 shares@ US$5.596.0% of flowCommon StockSEC:0001127602-21-018509:5
- 5,901 shares@ US$5.450.5% of flowCommon StockSEC:0001127602-21-018509:6
- 91,814 shares@ US$15.0222.8% of flowCommon StockSEC:0001127602-21-018509:7
- 24,959 shares@ US$4.7318.3% of flowCommon StockSEC:0001127602-21-018509:0
- 41,250 shares@ US$4.152.9% of flowCommon StockSEC:0001127602-21-007642:0
- 41,250 shares@ US$11.578.0% of flowCommon StockSEC:0001127602-21-007642:1
- 1,087 shares@ US$8.070.5% of flowCommon StockSEC:0001127602-19-000720:0
- 20,488 shares@ US$7.589.3% of flowCommon StockSEC:0001127602-18-036977:0
- 62,500 shares@ US$1.424.4% of flowCommon StockSEC:0001127602-18-025155:0
- 62,500 shares@ US$7.0322.0% of flowCommon StockSEC:0001127602-18-025155:1
- 42,112 shares@ US$2.585.2% of flowCommon StockSEC:0001127602-18-019981:0
- 42,112 shares@ US$6.3012.7% of flowCommon StockSEC:0001127602-18-019981:1
- 4,628 shares@ US$5.591.2% of flowCommon StockSEC:0001127602-18-002233:0
- 1,169 shares@ US$4.910.3% of flowCommon StockSEC:0001127602-18-000303:0
- 64,310 shares@ US$4.7214.6% of flowCommon StockSEC:0001127602-17-032183:0
- 5,761 shares@ US$5.951.8% of flowCommon StockSEC:0001127602-17-002248:0
- 2,081 shares@ US$6.330.7% of flowCommon StockSEC:0001127602-17-000069:0
25 of 65 declarations
